Squarepoint
MBX

Squarepoint’s MBX Biosciences MBX Stock Holding History

Squarepoint’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.9M Buy
97,215
+50,513
+108% +$1.72M ﹤0.01% 1912
2025
Q4 		$1.47M Buy
+46,702
New +$1.13M ﹤0.01% 2285
2025
Q2 		– Sell
-20,098
Closed -$148K – 5188
2025
Q1 		$148K Buy
+20,098
New +$213K ﹤0.01% 4111
2024
Q4 		– Sell
-16,470
Closed -$428K – 5587
2024
Q3 		$428K Buy
+16,470
New +$377K ﹤0.01% 3212

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Squarepoint's MBX Position: Q1 2026 in Review

Squarepoint increased its MBX Biosciences (MBX) stake by 108% in Q1 2026, buying an estimated $1.72M and bringing the position to 97,215 shares worth $2.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1912.

Squarepoint first reported a position in MBX in Q3 2024 and has held it in 4 quarters since. 157 funds tracked by Wall St. Rank hold MBX as of Q1 2026.

  • Squarepoint held 97,215 shares of MBX Biosciences worth $2.9M as of Q1 2026.
  • Squarepoint bought 50,513 MBX Biosciences shares in Q1 2026, an estimated $1.72M.
  • MBX Biosciences made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #1912 holding.
  • Squarepoint first reported a position in MBX Biosciences in Q3 2024 and has held it in 4 quarters since.
  • 157 funds tracked by Wall St. Rank held MBX Biosciences as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.